This site is intended for UK healthcare professionals

 
This promotional video has been developed, organised and funded by Novartis Pharmaceuticals UK Ltd. The content has been reviewed and approved by the sponsoring company and the speakers prior to broadcast. Editorial support for this video has been provided by OmniaMed Communications.
Click here to access ENTRESTO® (sacubitril/valsartan) prescribing information (externally hosted). Adverse event reporting can be found at the bottom of this page.
ENTRESTO® (sacubitril/valsartan) is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
novartis-logo-transparent
Entresto
1:07

Heart Failure Foundation Course: Optimising treatment for people with chronic heart failure with reduced ejection fraction

2 October 2025

Sponsored

1:07
Professor Jawad Khan (Consultant Interventional Cardiologist and Director of Medical Education, Sandwell and West Birmingham NHS Trust) introduces the second session of the Heart Failure Foundation Course 2025, which explores available treatment options and the practicalities of rapid uptitration of guideline-directed medication for patients with chronic heart failure with reduced ejection fraction.

Watch the full on-demand video and the other videos in this series on the Heart Failure Foundation Course 2025 resource site.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email [email protected] or call 01276 698370.

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.

BJC TV

To continue, please confirm that you are a UK healthcare professional.